Business Insider |
Biogen not pursuing a sale: source
Business Insider Meanwhile, Allergan recently announced the closing of a deal to sell its generics business to Teva Pharmaceutical Industries Ltd for more than $40 billion, providing Allergan with a substantial war chest that could be deployed for acquisitions. In ... Report: Biogen Targeted as Takeover Target |
Thursday, 4 August 2016
Biogen not pursuing a sale: source - Business Insider
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment